Is BioLife Solutions, Inc. overvalued or undervalued?

As of 28 February 2022, the valuation grade for BioLife Solutions, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health and market position. The company is currently considered overvalued given its negative performance metrics, including a P/E ratio of NA due to being loss-making, an EV to EBITDA of -1053.88, and a Price to Book Value of 3.20.
In comparison to its peers, BioLife Solutions, Inc. has a significantly worse EV to EBITDA ratio than Artivion, Inc. at 32.8893 and Silk Road Medical, Inc. at -18.1243, both of which are also classified as risky. Additionally, the company's return metrics show a year-to-date decline of 17.72%, contrasting with the S&P 500's gain of 2.44%, further reinforcing the notion that the stock is overvalued in its current state.